يعرض 101 - 110 نتائج من 758 نتيجة بحث عن '"CCR5 receptor antagonist"', وقت الاستعلام: 1.23s تنقيح النتائج
  1. 101
  2. 102
  3. 103
  4. 104
  5. 105
  6. 106
    دورية أكاديمية

    المساهمون: Maggi, P., Bruno, G., Perilli, F., Saracino, A., Volpe, A., Santoro, C., Ladisa, N., Angarano, G.

    العلاقة: info:eu-repo/semantics/altIdentifier/pmid/28064231; info:eu-repo/semantics/altIdentifier/wos/WOS:000395897100017; volume:31; issue:1; firstpage:125; lastpage:132; numberofpages:8; journal:IN VIVO; http://hdl.handle.net/11591/439493Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85011394808

  7. 107
  8. 108
  9. 109
  10. 110

    المساهمون: Silvestri, Guido

    المصدر: Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
    Consejería de Sanidad de la Comunidad de Madrid
    Serrano-Villar, S; Sainz, T; Ma, ZM; Utay, NS; Wook-Chun, T; Mann, S; et al.(2016). Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial. PLoS Pathogens, 12(1). doi: 10.1371/journal.ppat.1005381. UC Davis: Retrieved from: http://www.escholarship.org/uc/item/9gn0z3z1Test
    PLoS Pathogens, Vol 12, Iss 1, p e1005381 (2016)
    PLoS pathogens, vol 12, iss 1
    PLoS Pathogens
    PLoS Pathogens, Vol 13, Iss 5, p e1006368 (2017)
    Serrano-Villar, S; Sainz, T; Ma, Z-M; Utay, NS; Wook-Chun, T; Mann, S; et al.(2017). Correction: Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial.. PLoS pathogens, 13(5), e1006368. doi: 10.1371/journal.ppat.1006368. UC Davis: Retrieved from: http://www.escholarship.org/uc/item/1sc900c6Test
    PLoS pathogens, vol 13, iss 5
    PLoS pathogens, vol 12, iss 3
    PLoS Pathogens, Vol 12, Iss 3, p e1005540 (2016)

    مصطلحات موضوعية: Cyclopropanes, Male, 0301 basic medicine, Gut-associated lymphoid tissue, Integrase inhibitor, HIV Infections, Pilot Projects, Lymphocyte Activation, Raltegravir Potassium, law.invention, Maraviroc, chemistry.chemical_compound, Randomized controlled trial, T-Lymphocyte Subsets, law, Emtricitabine, Biology (General), lcsh:QH301-705.5, Mucosal immunity, Chromatography, High Pressure Liquid, Chromatography, Mucosal, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination, Flow Cytometry, 3. Good health, Drug Combinations, Infectious Diseases, medicine.anatomical_structure, 5.1 Pharmaceuticals, Medical Microbiology, Alkynes, High Pressure Liquid, 6.1 Pharmaceuticals, CCR5 Receptor Antagonists, HIV/AIDS, Female, Development of treatments and therapeutic interventions, Infection, Research Article, medicine.drug, lcsh:Immunologic diseases. Allergy, Adult, medicine.medical_specialty, Efavirenz, QH301-705.5, Anti-HIV Agents, Clinical Trials and Supportive Activities, 030106 microbiology, Immunology, Enzyme-Linked Immunosorbent Assay, CCR5 receptor antagonist, Biology, Microbiology, 03 medical and health sciences, Clinical Research, Cyclohexanes, Virology, Internal medicine, Genetics, medicine, Humans, HIV Integrase Inhibitors, Tenofovir Disoproxil Fumarate Drug Combination, Immunity, Mucosal, Molecular Biology, business.industry, Inflammatory and immune system, Immunity, Correction, Evaluation of treatments and therapeutic interventions, RC581-607, Triazoles, Raltegravir, Antiretroviral therapy, Benzoxazines, Regimen, Good Health and Well Being, 030104 developmental biology, lcsh:Biology (General), chemistry, Parasitology, Immunologic diseases. Allergy, lcsh:RC581-607, business

    وصف الملف: application/pdf